|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.04 HKD | +7.23% |
|
+16.94% | +19.71% |
| Apr. 12 | Keymed Biosciences Advances Solid Tumors Drug With First Patient Study | MT |
| Mar. 27 | Lepu Biopharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Lepu Biopharma Co., Ltd. reported earnings results for the half year ended June 30, 2023. For the half year, the company reported sales was CNY 153.55 million. Net loss was CNY 141.9 million compared to CNY 344.29 million a year ago.
Basic loss per share from continuing operations was CNY 0.09 compared to CNY 0.21 a year ago. Diluted loss per share from continuing operations was CNY 0.09 compared to CNY 0.21 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +19.71% | 1.07B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
LEPU BIOPHARMA CO., LTD. 
